Should All Patients With Pancreatic Cancer Receive Chemotherapy Before Surgery?-Reference-Cited by-同舟云学术

Should All Patients With Pancreatic Cancer Receive Chemotherapy Before Surgery?

Published:2020-09-01 Issue:9 Volume:155 Page:840
ISSN:2168-6254
Container-title:JAMA Surgery
language:en
Short-container-title:JAMA Surg

Author:

Ye Linda¹,Hines O. Joe¹

Affiliation:

1. Department of Surgery, David Geffen School of Medicine at University of California, Los Angeles

Publisher

American Medical Association (AMA)

Subject

Surgery

Link

https://jamanetwork.com/journals/jamasurgery/articlepdf/2768329/jamasurgery_ye_2020_ic_200028_1598967223.94259.pdf

Reference7 articles.

1. Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials.;Assifi;Surgery,2011

2. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.;Conroy;N Engl J Med,2011

3. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.;Von Hoff;N Engl J Med,2013

4. Response and survival associated with first-line FOLFIRINOX vs gemcitabine and nab-paclitaxel chemotherapy for localized pancreatic ductal adenocarcinoma.;Perri;JAMA Surg

5. CA19-9 normalization during pre-operative treatment predicts longer survival for patients with locally progressed pancreatic cancer.;Williams;J Gastrointest Surg,2016

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer;BMC Cancer;2021-08-19

2. Neoadjuvant Chemotherapy in Pancreatic Cancer;JAMA Surgery;2021-04-01